Antithrombin III (human and recombinant)

General information

Class/mechanism: Inhibitor of thrombin, which converts fibrinogen to fibrin in the coagulation cascade and subsequent development of thrombus. Clinical applications include management of patients with hereditary antithrombin III (AT-III) deficiency. Please choose from the products below to find specific drug/manufacturer information:

• Antithrombin III, human (Thrombate III)
• Antithrombin III, recombinant (ATryn)

Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, medscape, or the prescribing information.

Patient drug information

• Antithrombin III (human and recombinant) patient drug information (UpToDate)
• Brief patient counseling information can be found on page 15 of the ATryn package insert

Also known as

• Brand names: ATryn, Thrombate III